[1]
Zaki, A.M.; Van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New . Eng. J. Med., 2012, 367(19), 1814-1820.
[2]
Kandeel, M.; Elaiziz, M.; Kandeel, A.; Altaher, A.; Kitade, Y. Association of host tropism of Middle East syndrome coronavirus with the amino acid structure of host cell receptor dipeptidyl peptidase 4. Acta Virol., 2013, 58(4), 359-363.
[3]
Reusken, C.B.; Messadi, L.; Feyisa, A.; Ularamu, H.; Godeke, G.J.; Danmarwa, A.; Dawo, F.; Jemli, M.; Melaku, S.; Shamaki, D. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg. Infec. Dis., 2014, 20(8), 1370-1374.
[4]
Devi, J.P.; Noraini, W.; Norhayati, R.; Kheong, C.C.; Badrul, A.; Zainah, S.; Fadzilah, K.; Hirman, I.; Hakim, S.L.; Hisham, A.N. Laboratory-confirmed case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Malaysia: Preparedness and response. Euro Surveill., 2014, 19(18), pii20797.
[5]
Su, S.; Wong, G.; Liu, Y.; Gao, G.F.; Li, S.; Bi, Y. MERS in South Korea and China: A potential outbreak threat? Lancet, 2015, 385(9985), 2349-2350.
[6]
Shi, J.; Zhang, J.; Li, S.; Sun, J.; Teng, Y.; Wu, M.; Li, J.; Li, Y.; Hu, N.; Wang, H. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: An in silico approach applied to emerging infectious diseases. PloS One, 2015, 10(12), e0144475.
[7]
Lee, H.; Lei, H.; Santarsiero, B.D.; Gatuz, J.L.; Cao, S.; Rice, A.J.; Patel, K.; Szypulinski, M.Z.; Ojeda, I.; Ghosh, A.K. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem. Biol., 2015, 10(6), 1456-1465.
[8]
Wang, F.; Chen, C.; Tan, W.; Yang, K.; Yang, H. Structure of main protease from human coronavirus NL63: Insights for wide spectrum anti-coronavirus drug design. Sci. Rep., 2016, 6, 22677.
[9]
Wu, A.; Wang, Y.; Zeng, C.; Huang, X.; Xu, S.; Su, C.; Wang, M.; Chen, Y.; Guo, D. Prediction and biochemical analysis of putative cleavage sites of the 3C-like protease of Middle East respiratory syndrome coronavirus. Virus Res., 2015, 208, 56-65.
[10]
Lei, J.; Hilgenfeld, R. Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin. Virol. Sin., 2016, 31, 288-299.
[11]
Mielech, A.M.; Kilianski, A.; Baez-Santos, Y.M.; Mesecar, A.D.; Baker, S.C. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology, 2014, 450, 64-70.
[12]
Lin, M-H.; Chuang, S-J.; Chen, C-C.; Cheng, S-C.; Cheng, K-W.; Lin, C-H.; Sun, C-Y.; Chou, C-Y. Structural and functional characterization of MERS coronavirus papain-like protease. J. Biomed. Sci., 2014, 21(1), 1.
[13]
Cheng, K-W.; Cheng, S-C.; Chen, W-Y.; Lin, M-H.; Chuang, S-J.; Cheng, I-H.; Sun, C-Y.; Chou, C-Y. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res., 2015, 115, 9-16.
[14]
Kandeel, M.; Altaher, A.; Kitade, Y.; Abdelaziz, M.; Alnazawi, M.; Elshazli, K. Evolution of camel CYP2E1 and its associated power of binding toxic industrial chemicals and drugs. Comput. Biol. Chem., 2016, 64, 271-280.
[15]
Kandeel, M.; Kitade, Y. Computational analysis of siRNA recognition by the Ago2 PAZ domain and identification of the determinants of RNA-induced gene silencing. PloS One, 2013, 8, e57140.
[16]
Kandeel, M.; Kitade, Y. In silico molecular docking analysis of the human Argonaute 2 PAZ domain reveals insights into RNA interference. J. Comp. Aided Mol. Des., 2013, 27(7), 605-614.
[17]
Kandeel, M.; Ando, T.; Kitamura, Y.; Abdel-Aziz, M.; Kitade, Y. Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery. Parasitology, 2009, 136(01), 11-25.
[18]
Altaher, Y.; Kandeel, M. Molecular analysis of some camel cytochrome P450 enzymes reveals lower evolution and drug-binding properties. J. Biomol. Struct. Dynamics., 2016, 34(1), 115-124.
[19]
Altaher, Y.; Nakanishi, M.; Kandeel, M. Annotation of camel genome for estimation of drug binding power, evolution and adaption of cytochrome P450 1a2. Int. J. Pharmacol., 2015, 11(3), 243-247.
[20]
Krieger, E.; Koraimann, G.; Vriend, G. Increasing the precision of comparative models with YASARA NOVA-a self‐parameterizing force field. Proteins: Struct. Func. Bioinform., 2002, 47(3), 393-402.
[21]
Alfuwaires, M.; Altaher, A.; Kandeel, M. Molecular Dynamic studies of interferon and innate immunity resistance in MERS CoV non-structural protein 3. Biol. Pharmaceut . Bull., 2017, 40(3), 345-351.
[22]
Clasman, J.R.; Báez-Santos, Y.M.; Mettelman, R.C.; O’Brien, A.; Baker, S.C.; Mesecar, A.D. X-ray structure and enzymatic activity profile of a core papain-like protease of MERS coronavirus with utility for structure-based drug design. Scient. Rep., 2017, 7, 40292.
